These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24204271)

  • 1. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.
    Zellweger RM; Miller R; Eddy WE; White LJ; Johnston RE; Shresta S
    PLoS Pathog; 2013 Oct; 9(10):e1003723. PubMed ID: 24204271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice.
    Zheng X; Chen H; Wang R; Fan D; Feng K; Gao N; An J
    Front Cell Infect Microbiol; 2017; 7():175. PubMed ID: 28553618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
    Elong Ngono A; Shresta S
    Front Immunol; 2019; 10():1316. PubMed ID: 31244855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of Dengue Virus Maturation on Vaccine Induced Humoral Immunity in Mice.
    Scott CAP; Amarilla AA; Bibby S; Newton ND; Hall RA; Hobson-Peters J; Muller DA; Chappell KJ; Young PR; Modhiran N; Watterson D
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
    Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Modified NS1 and NS3 as a Novel Vaccine Strategy against Dengue Virus Infection.
    Kao YS; Yu CY; Huang HJ; Tien SM; Wang WY; Yang M; Anderson R; Yeh TM; Lin YS; Wan SW
    J Immunol; 2019 Oct; 203(7):1909-1917. PubMed ID: 31451673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.
    Holman DH; Wang D; Raviprakash K; Raja NU; Luo M; Zhang J; Porter KR; Dong JY
    Clin Vaccine Immunol; 2007 Feb; 14(2):182-9. PubMed ID: 17192403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003.
    Waickman AT; Friberg H; Gargulak M; Kong A; Polhemus M; Endy T; Thomas SJ; Jarman RG; Currier JR
    Front Immunol; 2019; 10():1778. PubMed ID: 31417556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated D2 16681-PDK53 vaccine: defining humoral and cell-mediated immunity.
    Rabablert J; Yoksan S
    Curr Pharm Des; 2009; 15(11):1203-11. PubMed ID: 19355961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges for the formulation of a universal vaccine against dengue.
    Chokephaibulkit K; Perng GC
    Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell immunity to dengue virus and implications for vaccine design.
    Rivino L
    Expert Rev Vaccines; 2016; 15(4):443-53. PubMed ID: 26560171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.
    Whitehead SS; Subbarao K
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress towards a dengue vaccine.
    Webster DP; Farrar J; Rowland-Jones S
    Lancet Infect Dis; 2009 Nov; 9(11):678-87. PubMed ID: 19850226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.
    Aberle JH; Aberle SW; Kofler RM; Mandl CW
    J Virol; 2005 Dec; 79(24):15107-13. PubMed ID: 16306582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune correlates for dengue vaccine development.
    Srikiatkhachorn A; Yoon IK
    Expert Rev Vaccines; 2016; 15(4):455-65. PubMed ID: 26560015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human CD4
    Angelo MA; Grifoni A; O'Rourke PH; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
    J Virol; 2017 Mar; 91(5):. PubMed ID: 27974563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
    Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.